ctDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSCLC
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorFang Wu
About this trial
This study aims to explore the correlation of circulating tumor DNA(ctDNA) and the risk of progression in patients with advanced NSCLC who have long-term benefit from first-line immunotherapy (PFS 12 months)
Eligibility criteria
Qualifiers
Age ≥ 18 years old
Advanced non-small cell lung cancer (stage IIIB-IV), pathological types limited to squamous cell carcinoma or non-squamous cell carcinoma, driver gene mutations (EGFR/ALK/ROS1) were negative
General condition: ECOG score 0 or 1
First-line monotherapy or combination immunotherapy
Disqualifiers
Serious primary diseases of the heart, liver and kidney
Other malignant tumors within 3 years prior to diagnosis of NSCLC
Women in pregnancy and lactation
The active stage of human immunodeficiency virus (HIV) infection
Trial design
Treatments tested in this trial
- ctDNA detection
Treatment groups
100 Participants
are divided into 2 treatment groupsSponsors and collaborators
Fang Wu
Lead sponsor
Second Xiangya Hospital of Central South University
Sponsor institution
Sun Yat-Sen University Cancer Center
Collaborator
First Affiliated Hospital Xi'an Jiaotong University
Collaborator
Fujian Cancer Hospital
Collaborator
Third Affiliated Hospital of Third Military Medical University
Collaborator
Xiangya Hospital of Central South University
Collaborator
Qinghai Province Fifth People's Hospital
Collaborator
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborator
Zhejiang Provincial People's Hospital
Collaborator
Hunan Province Tumor Hospital
Collaborator
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Collaborator
Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborator
Zhejiang Cancer Hospital
Collaborator
The First Affiliated Hospital of Guangzhou Medical University
Collaborator
Inner Mongolia People's Hospital
Collaborator
Guizhou Provincial People's Hospital
Collaborator
The Third Xiangya Hospital of Central South University
Collaborator
Yueyang Central Hospital
Collaborator
ZhuZhou Central Hospital
Collaborator
Zhangjiajie Affiliated Hospital of Hunan Normal University
Collaborator
Loudi Central Hospital
Collaborator
Chang Sha First Hospital
Collaborator
Source ClinicalTrials.gov